NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.

Last update: Oct 16, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) was identified as a decent value stock by our stock screener. NASDAQ:BMRN scores well on profitability, solvency and liquidity. At the same time it seems to be priced very reasonably. We'll explore this a bit deeper below.

Valuation Analysis for NASDAQ:BMRN

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:BMRN scores a 7 out of 10:

Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.69% of the companies listed in the same industry.
94.69% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.34% of the companies listed in the same industry.
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 65.82% in the coming years. This may justify a more expensive valuation.

Exploring NASDAQ:BMRN's Profitability

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:BMRN scores a 7 out of 10:

BMRN has a better Return On Assets (3.63%) than 94.51% of its industry peers.
Looking at the Return On Equity, with a value of 4.85%, BMRN belongs to the top of the industry, outperforming 94.69% of the companies in the same industry.
BMRN's Return On Invested Capital of 3.66% is amongst the best of the industry. BMRN outperforms 94.51% of its industry peers.
Looking at the Profit Margin, with a value of 9.91%, BMRN belongs to the top of the industry, outperforming 95.58% of the companies in the same industry.
With an excellent Operating Margin value of 10.73%, BMRN belongs to the best of the industry, outperforming 95.04% of the companies in the same industry.
With an excellent Gross Margin value of 80.07%, BMRN belongs to the best of the industry, outperforming 87.26% of the companies in the same industry.

Assessing Health for NASDAQ:BMRN

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:BMRN was assigned a score of 5 for health:

BMRN has an Altman-Z score of 5.30. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN has a better Altman-Z score (5.30) than 79.65% of its industry peers.
BMRN has a Debt to FCF ratio of 5.12. This is amongst the best in the industry. BMRN outperforms 94.69% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that BMRN is not too dependend on debt financing.
BMRN has a Current Ratio of 3.05. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.

Understanding NASDAQ:BMRN's Growth

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:BMRN, the assigned 7 reflects its growth potential:

BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.15%, which is quite impressive.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.84%.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 49.08% on average per year.
Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 11.86% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.

Check the latest full fundamental report of BMRN for a complete fundamental analysis.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.